AI ASSISTANT
Ask DrugCentral
Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIYour question
Ask in your own words. Each question is answered independently.
Explore sample questions
Select a question to fill the editor, then ask it or make it your own.
DrugCentral answer
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
About Ask DrugCentral
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
General architecture
- Ask a questionThe browser sends your question to the same-origin Django chat API.
- Retrieve and generateThe API forwards the question to the configured DrugCentral retrieval-augmented generation (RAG) service, which returns an AI-generated answer.
- Explore the answerThe app resolves cited drug-card names and displays the answer with links to drug records.
Using the assistant
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
darifenacin 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| muscarinic receptors antagonists | 784 | 133099-04-4 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
a competitive muscarinic receptor antagonist with greater affinity for the M3 receptor than for the other known muscarinic receptors, M3 receptors are involved in contraction of human bladder and gastrointestinal smooth muscle, saliva production, and iris sphincter function
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
| Dose | Unit | Route |
|---|---|---|
| 7.50 | mg | O |
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| BDDCS (Biopharmaceutical Drug Disposition Classification System) | 1 | Benet LZ, Broccatelli F, Oprea TI |
| EoM (Fraction excreted unchanged in urine) | 12.50 % | Benet LZ, Broccatelli F, Oprea TI |
| MRTD (Maximum Recommended Therapeutic Daily Dose) | 0.41 µM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
| BA (Bioavailability) | 17 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
| Vd (Volume of distribution) | 2.60 L/kg | Lombardo F, Berellini G, Obach RS |
| CL (Clearance) | 12 mL/min/kg | Lombardo F, Berellini G, Obach RS |
| fu (Fraction unbound in plasma) | 0.02 % | Lombardo F, Berellini G, Obach RS |
| t_half (Half-life) | 3.60 hours | Lombardo F, Berellini G, Obach RS |
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| azlogd74 | LogD at pH 7.4 | 2.616 | High | 1 | |
| caco2-efflux | Caco-2 efflux ratio (BA/AB) | 5.821 | High | 1 | |
| caco2-intrinsic-papp | Caco-2 intrinsic apparent permeability | 14.421 | 10^-6 cm/s | High | 1 |
| dh-clint | Dog hepatocyte intrinsic clearance | 18.155 | uL/min/10^6 cells | High | 1 |
| dppb | Dog plasma protein binding (% unbound) | 8.200 | % | High | 1 |
| fcs-ppb | Fetal calf serum protein binding (% unbound) | 19.350 | % | High | 1 |
| herg | hERG pIC50 | 5.935 | pIC50 | High | 1 |
| hh-clint | Human hepatocyte intrinsic clearance | 25.351 | uL/min/10^6 cells | High | 1 |
| hlm-clint | Human liver microsomal intrinsic clearance | 302.691 | uL/min/mg protein | High | 1 |
| hppb | Human plasma protein binding (% unbound) | 11.440 | % | High | 1 |
| kinase-safety-class | ACVR2B,AKT2,AKT3,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK5,CDK9,EIF2AK3,EPHB4,ERBB2,GRK2,ITK,JAK3,MAP3K7,MAPK10,MAPK12,MAPK7,MAPKAPK2,MET,NTRK2,PDK2,PDK4,PIK3CB,PIM2,PRKDC,TEK,TGFBR1 | 30 | |||
| kinase-selectivity-class | AXL,EIF2AK3,GRK2,PDK4 | 4 | |||
| mdck-mdr1-efflux | MDCK-MDR1 efflux ratio | 7.228 | High | 1 | |
| mh-clint | Mouse hepatocyte intrinsic clearance | 121.899 | High | 1 | |
| mppb | Mouse plasma protein binding (% unbound) | 12.910 | High | 1 | |
| nih-mdck-mdr1-efflux | NIH MDCK-MDR1 efflux ratio | 28.249 | High | 1 | |
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 | |||
| pld-class | Phospholipidosis risk class (1 = positive, 0 = negative) | 1 | High | 1 | |
| pppb | Pig plasma protein binding (% unbound) | 22.070 | % | High | 1 |
| rh-clint | Rat hepatocyte intrinsic clearance | 146.555 | uL/min/10^6 cells | High | 1 |
| rh-fuinc | Rat hepatocyte fraction unbound in incubation | 43.360 | % | High | 1 |
| rppb | Rat plasma protein binding (% unbound) | 14.320 | % | High | 1 |
| solubility-dd | Solubility at pH 7.4 in DMSO | 334.965 | uM | High | 1 |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Oct. 22, 2004 | EMA | Merus Labs Luxco S.a R.L. | |
| Dec. 22, 2004 | FDA | WARNER CHILCOTT LLC |
FDA Adverse Event Reporting System (Female)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Pneumonia viral | 513.45 | 35.03 | 107 | 3289 | 8716 | 90616335 |
| Soft tissue disorder | 417.90 | 35.03 | 80 | 3316 | 4210 | 90620841 |
| Herpes zoster | 388.37 | 35.03 | 142 | 3254 | 94502 | 90530549 |
| Liver function test abnormal | 260.03 | 35.03 | 90 | 3306 | 50755 | 90574296 |
| Oral pain | 227.40 | 35.03 | 73 | 3323 | 32610 | 90592441 |
| Leukopenia | 209.98 | 35.03 | 93 | 3303 | 100617 | 90524434 |
| Asphyxia | 201.96 | 35.03 | 48 | 3348 | 7055 | 90617996 |
| Arteriosclerosis coronary artery | 177.80 | 35.03 | 46 | 3350 | 9557 | 90615494 |
| Arthritis | 176.18 | 35.03 | 97 | 3299 | 167218 | 90457833 |
| Peripheral swelling | 161.92 | 35.03 | 129 | 3267 | 412977 | 90212074 |
| Blood cholesterol increased | 151.47 | 35.03 | 95 | 3301 | 207917 | 90417134 |
| Fibromyalgia | 149.68 | 35.03 | 94 | 3302 | 206175 | 90418876 |
| Synovitis | 131.15 | 35.03 | 104 | 3292 | 329648 | 90295403 |
| Anaemia | 112.61 | 35.03 | 98 | 3298 | 352704 | 90272347 |
| Infection | 87.16 | 35.03 | 86 | 3310 | 362008 | 90263043 |
| Tenderness | 83.32 | 35.03 | 33 | 3363 | 26835 | 90598216 |
| Joint swelling | 79.97 | 35.03 | 96 | 3300 | 503204 | 90121847 |
| Therapeutic product effect incomplete | 57.90 | 35.03 | 52 | 3344 | 193844 | 90431207 |
| Drug ineffective | 49.02 | 35.03 | 137 | 3259 | 1384161 | 89240890 |
| Soft tissue swelling | 48.05 | 35.03 | 11 | 3385 | 1367 | 90623684 |
| Complement factor C4 decreased | 37.99 | 35.03 | 7 | 3389 | 296 | 90624755 |
| Complement factor C3 decreased | 37.69 | 35.03 | 7 | 3389 | 309 | 90624742 |
FDA Adverse Event Reporting System (Male)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Duplicate therapy error | 47.77 | 43.92 | 7 | 400 | 289 | 42620639 |
FDA Adverse Event Reporting System (Geriatric)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Pneumonia viral | 326.28 | 32.94 | 72 | 2801 | 11085 | 110575341 |
| Soft tissue disorder | 240.56 | 32.94 | 46 | 2827 | 3478 | 110582948 |
| Herpes zoster | 212.08 | 32.94 | 86 | 2787 | 108293 | 110478133 |
| Asphyxia | 191.30 | 32.94 | 49 | 2824 | 14166 | 110572260 |
| Arteriosclerosis coronary artery | 150.77 | 32.94 | 46 | 2827 | 25072 | 110561354 |
| Liver function test abnormal | 125.39 | 32.94 | 52 | 2821 | 68898 | 110517528 |
| Oral pain | 117.41 | 32.94 | 42 | 2831 | 37402 | 110549024 |
| Arthritis | 99.66 | 32.94 | 59 | 2814 | 167527 | 110418899 |
| Fibromyalgia | 95.99 | 32.94 | 58 | 2815 | 170851 | 110415575 |
| Peripheral swelling | 95.89 | 32.94 | 81 | 2792 | 403953 | 110182473 |
| Leukopenia | 95.36 | 32.94 | 55 | 2818 | 148736 | 110437690 |
| Blood cholesterol increased | 91.82 | 32.94 | 58 | 2815 | 184727 | 110401699 |
| Synovitis | 88.69 | 32.94 | 66 | 2807 | 274026 | 110312400 |
| Tenderness | 73.71 | 32.94 | 28 | 2845 | 29409 | 110557017 |
| Therapeutic product effect incomplete | 59.45 | 32.94 | 48 | 2825 | 223757 | 110362669 |
| Joint swelling | 51.01 | 32.94 | 60 | 2813 | 442785 | 110143641 |
| Anaemia | 46.95 | 32.94 | 64 | 2809 | 547022 | 110039404 |
| Infection | 46.62 | 32.94 | 52 | 2821 | 362148 | 110224278 |
| Urinary tract infection | 42.24 | 32.94 | 47 | 2826 | 326235 | 110260191 |
| Complement factor C4 decreased | 39.29 | 32.94 | 7 | 2866 | 356 | 110586070 |
| Complement factor C3 decreased | 38.95 | 32.94 | 7 | 2866 | 374 | 110586052 |
| Soft tissue swelling | 38.66 | 32.94 | 9 | 2864 | 1740 | 110584686 |
| Duplicate therapy error | 37.96 | 32.94 | 7 | 2866 | 432 | 110585994 |
| Neuralgia | 33.88 | 32.94 | 19 | 2854 | 48459 | 110537967 |
| Arthralgia | 33.79 | 32.94 | 67 | 2806 | 779565 | 109806861 |
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | G04BD10 | GENITO URINARY SYSTEM AND SEX HORMONES UROLOGICALS UROLOGICALS Drugs for urinary frequency and incontinence |
| FDA MoA | N0000000125 | Cholinergic Muscarinic Antagonists |
| MeSH PA | D018377 | Neurotransmitter Agents |
| MeSH PA | D018678 | Cholinergic Agents |
| MeSH PA | D018680 | Cholinergic Antagonists |
| MeSH PA | D018727 | Muscarinic Antagonists |
| MeSH PA | D064804 | Urological Agents |
| FDA EPC | N0000175700 | Cholinergic Muscarinic Antagonist |
| CHEBI has role | CHEBI:48876 | muscarinic antagonist |
| CHEBI has role | CHEBI:53784 | antispasmodic drug |
Related Drugs by ATC class:
G04BD Drugs for urinary frequency and incontinence 13 drugs
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Urgent desire to urinate | indication | 75088002 | |
| Urge incontinence of urine | indication | 87557004 | |
| Bladder muscle dysfunction - overactive | indication | 236633002 | |
| Increased Urinary Frequency | indication | ||
| Angioedema | contraindication | 41291007 | DOID:1558 |
| Hepatic failure | contraindication | 59927004 | |
| Ulcerative colitis | contraindication | 64766004 | DOID:8577 |
| Myasthenia gravis | contraindication | 91637004 | DOID:437 |
| Gastrointestinal obstruction | contraindication | 126765001 | |
| Acute constipation | contraindication | 197119006 | |
| Disease of liver | contraindication | 235856003 | DOID:409 |
| Bladder outflow obstruction | contraindication | 236645006 | |
| Retention of urine | contraindication | 267064002 | |
| Gastric retention | contraindication | 307227006 | |
| Angle-closure glaucoma | contraindication | 392291006 | DOID:13550 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 8.6 | Basic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Muscarinic acetylcholine receptor M3 | GPCR | ANTAGONIST | Kd | 9.52 | CHEMBL | CHEMBL | |||
| Beta-2 adrenergic receptor | GPCR | Ki | 7.21 | CHEMBL | |||||
| D(2) dopamine receptor | GPCR | IC50 | 4.60 | CHEMBL | |||||
| Muscarinic acetylcholine receptor M1 | GPCR | Ki | 8.30 | CHEMBL | |||||
| Muscarinic acetylcholine receptor M2 | GPCR | ANTAGONIST | Ki | 7.60 | CHEMBL | ||||
| Muscarinic acetylcholine receptor M4 | GPCR | Ki | 8.10 | CHEMBL | |||||
| Muscarinic acetylcholine receptor M5 | GPCR | Ki | 8.64 | CHEMBL | |||||
| Beta-1 adrenergic receptor | GPCR | IC50 | 6.50 | CHEMBL | |||||
| Muscarinic acetylcholine receptor M2 | GPCR | Ki | 7.20 | CHEMBL | |||||
| Muscarinic acetylcholine receptor M3 | GPCR | Ki | 8.60 | CHEMBL |
External reference:
| ID | Source |
|---|---|
| D01699 | KEGG_DRUG |
| 133099-07-7 | SECONDARY_CAS_RN |
| 136198 | RXNORM |
| C0529351 | UMLSCUI |
| CHEBI:391960 | CHEBI |
| A1CIW | PDB_CHEM_ID |
| CHEMBL1346 | ChEMBL_ID |
| CHEMBL1200935 | ChEMBL_ID |
| DB00496 | DRUGBANK_ID |
| C101207 | MESH_SUPPLEMENTAL_RECORD_UI |
| 444031 | PUBCHEM_CID |
| 321 | IUPHAR_LIGAND_ID |
| 7153 | INN_ID |
| APG9819VLM | UNII |
| 19114 | MMSL |
| 64038 | MMSL |
| d05422 | MMSL |
| 008802 | NDDF |
| 008812 | NDDF |
| 416140008 | SNOMEDCT_US |
| 416385001 | SNOMEDCT_US |
| 426766002 | SNOMEDCT_US |
| 4024903 | VANDF |
| APG9819VLM | INXIGHT DRUGS |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| Darifenacin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 13668-202 | TABLET, EXTENDED RELEASE | 7.50 mg | ORAL | ANDA | 25 sections |
| Darifenacin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 13668-203 | TABLET, EXTENDED RELEASE | 15 mg | ORAL | ANDA | 25 sections |
| Darifenacin | Human Prescription Drug Label | 1 | 16571-767 | TABLET, FILM COATED, EXTENDED RELEASE | 7.50 mg | ORAL | ANDA | 26 sections |
| Darifenacin | Human Prescription Drug Label | 1 | 16571-768 | TABLET, FILM COATED, EXTENDED RELEASE | 15 mg | ORAL | ANDA | 26 sections |
| Darifenacin | Human Prescription Drug Label | 1 | 33342-276 | TABLET, EXTENDED RELEASE | 7.50 mg | ORAL | ANDA | 26 sections |
| Darifenacin | Human Prescription Drug Label | 1 | 33342-277 | TABLET, EXTENDED RELEASE | 15 mg | ORAL | ANDA | 26 sections |
| DARIFENACIN | Human Prescription Drug Label | 1 | 46708-223 | TABLET, EXTENDED RELEASE | 7.50 mg | ORAL | ANDA | 26 sections |
| DARIFENACIN | Human Prescription Drug Label | 1 | 46708-224 | TABLET, EXTENDED RELEASE | 15 mg | ORAL | ANDA | 26 sections |
| Darifenacin | Human Prescription Drug Label | 1 | 52605-067 | TABLET, EXTENDED RELEASE | 7.50 mg | ORAL | ANDA | 27 sections |
| Darifenacin | Human Prescription Drug Label | 1 | 52605-068 | TABLET, EXTENDED RELEASE | 15 mg | ORAL | ANDA | 27 sections |
| Enablex | HUMAN PRESCRIPTION DRUG LABEL | 1 | 54868-5363 | TABLET, EXTENDED RELEASE | 15 mg | ORAL | NDA | 25 sections |
| Enablex | HUMAN PRESCRIPTION DRUG LABEL | 1 | 54868-5704 | TABLET, EXTENDED RELEASE | 7.50 mg | ORAL | NDA | 25 sections |
| DARIFENACIN | Human Prescription Drug Label | 1 | 62332-223 | TABLET, EXTENDED RELEASE | 7.50 mg | ORAL | ANDA | 26 sections |
| DARIFENACIN | Human Prescription Drug Label | 1 | 62332-224 | TABLET, EXTENDED RELEASE | 15 mg | ORAL | ANDA | 26 sections |
| Darifenacin | Human Prescription Drug Label | 1 | 65862-861 | TABLET, FILM COATED, EXTENDED RELEASE | 7.50 mg | ORAL | ANDA | 26 sections |
| Darifenacin | Human Prescription Drug Label | 1 | 65862-862 | TABLET, FILM COATED, EXTENDED RELEASE | 15 mg | ORAL | ANDA | 26 sections |
| Darifenacin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 69097-431 | TABLET, EXTENDED RELEASE | 7.50 mg | ORAL | ANDA | 25 sections |
| Darifenacin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 69097-431 | TABLET, EXTENDED RELEASE | 7.50 mg | ORAL | ANDA | 25 sections |
| Darifenacin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 69097-432 | TABLET, EXTENDED RELEASE | 15 mg | ORAL | ANDA | 25 sections |
| Darifenacin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 69097-432 | TABLET, EXTENDED RELEASE | 15 mg | ORAL | ANDA | 25 sections |
| Darifenacin 7.5 mg | HUMAN PRESCRIPTION DRUG LABEL | 1 | 70700-182 | TABLET, EXTENDED RELEASE | 7.50 mg | ORAL | ANDA | 25 sections |
| Darifenacin 15 mg | HUMAN PRESCRIPTION DRUG LABEL | 1 | 70700-183 | TABLET, EXTENDED RELEASE | 15 mg | ORAL | ANDA | 25 sections |
| darifenacin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 70754-161 | TABLET, FILM COATED, EXTENDED RELEASE | 7.50 mg | ORAL | ANDA | 28 sections |
| darifenacin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 70754-162 | TABLET, FILM COATED, EXTENDED RELEASE | 15 mg | ORAL | ANDA | 28 sections |
| Darifenacin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 72162-2570 | TABLET, EXTENDED RELEASE | 7.50 mg | ORAL | ANDA | 25 sections |
| Darifenacin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 72162-2571 | TABLET, EXTENDED RELEASE | 15 mg | ORAL | ANDA | 25 sections |